title: Inhibitor of DNA Binding 4 (ID4) is highly expressed in human melanoma tissues and may function to restrict normal differentiation of melanoma cells.
abstract: Melanoma tissues and cell lines are heterogeneous, and include cells with invasive, proliferative, stem cell-like, and differentiated properties. Such heterogeneity likely contributes to the aggressiveness of the disease and resistance to therapy. One model suggests that heterogeneity arises from rare cancer stem cells (CSCs) that produce distinct cancer cell lineages. Another model suggests that heterogeneity arises through reversible cellular plasticity, or phenotype-switching. Recent work indicates that phenotype-switching may include the ability of cancer cells to dedifferentiate to a stem cell-like state. We set out to investigate the phenotype-switching capabilities of melanoma cells, and used unbiased methods to identify genes that may control such switching. We developed a system to reversibly synchronize melanoma cells between 2D-monolayer and 3D-stem cell-like growth states. Melanoma cells maintained in the stem cell-like state showed a striking upregulation of a gene set related to development and neural stem cell biology, which included SRY-box 2 (SOX2) and Inhibitor of DNA Binding 4 (ID4). A gene set related to cancer cell motility and invasiveness was concomitantly downregulated. Intense and pervasive ID4 protein expression was detected in human melanoma tissue samples, suggesting disease relevance for this protein. SiRNA knockdown of ID4 inhibited switching from monolayer to 3D-stem cell-like growth, and instead promoted switching to a highly differentiated, neuronal-like morphology. We suggest that ID4 is upregulated in melanoma as part of a stem cell-like program that facilitates further adaptive plasticity. ID4 may contribute to disease by preventing stem cell-like melanoma cells from progressing to a normal differentiated state. This interpretation is guided by the known role of ID4 as a differentiation inhibitor during normal development. The melanoma stem cell-like state may be protected by factors such as ID4, thereby potentially identifying a new therapeutic vulnerability to drive differentiation to the normal cell phenotype.
authors: Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania, United States of America.
authors: Yuval
authors: Y
authors: Peretz
authors: Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania, United States of America.
authors: Hong
authors: H
authors: Wu
authors: Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania, United States of America.
authors: Shayan
authors: S
authors: Patel
authors: Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania, United States of America.
authors: Alfonso
authors: A
authors: Bellacosa
authors: Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania, United States of America.
authors: Richard A
authors: RA
authors: Katz
mesh_terms: D002448:Cell Adhesion; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D015972:Gene Expression Regulation, Neoplastic; D055785:Gene Knockdown Techniques; D006801:Humans; D051796:Inhibitor of Differentiation Proteins / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D008545:Melanoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D009361:Neoplasm Invasiveness; D014411:Neoplastic Stem Cells / Q000473:pathology; D010641:Phenotype; D034741:RNA, Small Interfering / Q000235:genetics; D055748:SOXB1 Transcription Factors / Q000172:deficiency / Q000235:genetics; D014158:Transcription, Genetic
chemical_list: C490128:ID4 protein, human; D051796:Inhibitor of Differentiation Proteins; D034741:RNA, Small Interfering; C527782:SOX2 protein, human; D055748:SOXB1 Transcription Factors
references: Genes Dev. 2008 Aug 1;22(15):2028-33
references: 18676808
references: Nat Med. 2009 Sep;15(9):1010-2
references: 19734877
references: Int J Radiat Biol. 2007 Nov-Dec;83(11-12):849-71
references: 18058370
references: Cancer Cell. 2012 Mar 20;21(3):283-96
references: 22439924
references: Trends Cell Biol. 2010 May;20(5):233-43
references: 20153966
references: J Biol Chem. 2005 Feb 11;280(6):4313-20
references: 15563451
references: Oncogene. 2011 Jul 7;30(27):3036-48
references: 21358674
references: Blood. 2011 Jan 20;117(3):862-71
references: 21098398
references: Mol Cancer Ther. 2006 May;5(5):1136-44
references: 16731745
references: Eur J Cancer. 2013 Apr;49(6):1297-304
references: 23290787
references: Am J Pathol. 1993 Aug;143(2):528-37
references: 8342600
references: Exp Dermatol. 2011 Apr;20(4):339-45
references: 21410764
references: Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19726-31
references: 19033461
references: BMC Clin Pathol. 2005 Jul 15;5:6
references: 16018821
references: Cancer Res. 1990 Apr 15;50(8):2296-302
references: 2156614
references: Lab Invest. 2011 May;91(5):647-64
references: 21445060
references: Nature. 2013 Sep 19;501(7467):328-37
references: 24048065
references: J Invest Dermatol. 2010 Jul;130(7):1769-71
references: 20548315
references: J Biomed Sci. 2010;17:87
references: 21080952
references: Lab Invest. 2014 Jan;94(1):13-30
references: 24126889
references: J Biomed Biotechnol. 2012;2012:254085
references: 22899882
references: Dev Biol. 2005 Apr 15;280(2):386-95
references: 15882580
references: Nat Med. 2011 Mar;17(3):313-9
references: 21386835
references: J Invest Dermatol. 2009 Apr;129(4):945-53
references: 18923447
references: Br J Cancer. 2007 Apr 10;96(7):1072-82
references: 17342088
references: Proc Natl Acad Sci U S A. 2011 May 10;108(19):7838-43
references: 21521790
references: Arch Pathol Lab Med. 2010 Dec;134(12):1750-7
references: 21128771
references: J Invest Dermatol. 2013 May;133(5):1384-7
references: 23389394
references: J Neurobiol. 2006 Apr;66(5):421-36
references: 16425216
references: Mol Biol Rep. 2011 Oct;38(7):4637-42
references: 21132377
references: Cancer Res. 2011 May 1;71(9):3410-21
references: 21531766
references: Stem Cells Dev. 2010 Nov;19(11):1663-78
references: 20594031
references: Eur J Cancer. 2007 Mar;43(5):935-46
references: 17320377
references: N Engl J Med. 2010 Aug 26;363(9):809-19
references: 20818844
references: Oncotarget. 2010 May;1(1):48-58
references: 21293053
references: Nature. 2008 Dec 4;456(7222):593-8
references: 19052619
references: Nature. 2010 Jul 1;466(7302):133-7
references: 20596026
references: Cancer Res. 2010 Mar 1;70(5):2030-40
references: 20145155
references: Development. 2004 Nov;131(21):5441-8
references: 15469968
references: Cancer Res. 2012 Feb 1;72(3):576-80
references: 22298594
references: N Engl J Med. 2013 Jul 11;369(2):134-44
references: 23724846
references: Nat Rev Genet. 2008 Feb;9(2):115-28
references: 18202695
references: Cell Stem Cell. 2009 Jun 5;4(6):466-7
references: 19497271
references: Pigment Cell Melanoma Res. 2010 Dec;23(6):746-59
references: 20726948
references: Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3752-7
references: 16505384
references: EMBO J. 2000 May 2;19(9):1998-2007
references: 10790366
references: Haematologica. 2003 Sep;88(9):994-1001
references: 12969807
references: PLoS One. 2011;6(11):e27079
references: 22073257
references: Cancer Cell. 2003 Jun;3(6):525-30
references: 12842081
references: Carcinogenesis. 2014 Apr;35(4):951-8
references: 24343358
references: Int J Cancer. 1991 Jan 21;47(2):227-37
references: 1671030
references: Proc Natl Acad Sci U S A. 1976 Sep;73(9):3278-82
references: 1067619
references: Oncogene. 2010 Jul 1;29(26):3793-802
references: 20453881
references: Nature. 2012 Aug 23;488(7412):462-3
references: 22919708
references: Cancer. 2013 Mar 1;119(5):1004-12
references: 23132729
references: Cancer Lett. 2013 Sep 10;338(1):69-73
references: 22445909
references: J Cutan Pathol. 2008 May;35(5):433-44
references: 18399807
references: Melanoma Res. 2012 Jun;22(3):184-94
references: 22454190
references: Cancer Lett. 2013 Sep 10;338(1):74-81
references: 23073475
references: Cells Tissues Organs. 2013;198(1):12-21
references: 23774755
references: Semin Oncol. 2014 Apr;41(2):259-66
references: 24787297
references: Trends Cell Biol. 2003 Aug;13(8):410-8
references: 12888293
references: J Cancer. 2010 Jun 01;1:1-5
references: 20842217
references: Cancer Cell. 2010 Nov 16;18(5):510-23
references: 21075313
references: Mod Pathol. 2006 Jul;19(7):931-41
references: 16575399
references: Pigment Cell Melanoma Res. 2012 Sep;25(5):573-83
references: 22681858
references: J Cell Physiol. 2005 Aug;204(2):522-31
references: 15744745
references: Cancer Res. 2005 Oct 15;65(20):9328-37
references: 16230395
references: BMC Cancer. 2009;9:173
references: 19500415
references: Nat Rev Cancer. 2005 Aug;5(8):603-14
references: 16034366
references: Methods Enzymol. 2006;411:134-93
references: 16939790
references: J Invest Dermatol. 2006 Jan;126(1):142-53
references: 16417230
references: Blood. 2009 Apr 16;113(16):3655-65
references: 19221035
references: Sci Transl Med. 2012 Aug 15;4(147):147ra112
references: 22896676
references: PLoS One. 2011;6(4):e18784
references: 21526207
references: J Neurochem. 2008 Jan;104(2):316-24
references: 17944878
references: Nature. 2012 Oct 18;490(7420):412-6
references: 23051752
references: Melanoma Res. 2012 Jun;22(3):215-24
references: 22495670
references: Breast Cancer Res Treat. 2012 Aug;135(1):93-102
references: 22538771
references: N Engl J Med. 2006 Jul 6;355(1):51-65
references: 16822996
references: Am J Pathol. 2003 Dec;163(6):2495-502
references: 14633621
references: J Biol Chem. 2010 Jan 1;285(1):422-33
references: 19880521